Developing the most revolutionary oncolytic immunotherapeutic candidates
to provide advanced targeted treatments for solid cancer
THE WORLD VACCINE CONGRESS PRESENTATION
Seneca's primary asset, SVV-001, is an oncolytic virus that selectively replicates in tumor cells expressing the TEM8 receptor, while being non-pathogenic in both humans and animals. Extensively evaluated in over 30 preclinical cancer models and three clinical trials for solid cancers including neuroendocrine and pediatric tumors. Combining SVV-001 with immune modulators, cytokines, and checkpoint inhibitors has shown synergistic anti-tumor effects in various animal studies.
KOL WEBINAR ON SENECA VALLEY VIRUS & TEM 8
In this KOL Webinar, SVV is being analyzed as an ideal cancer therapeutic by explaining advances from an structural biology perspective (Mihnea Bostina), clinical perspective (Aman Chauhan) and industry perspective (Paul Hallenbeck).